Combination thymosin alpha-1 + famciclovir induced HBeAg seroconversion in some immune-tolerant chronic hepatitis B patients by activating HBV-specific T-cell responses — a population that usually doesn't respond to treatment.
Tolerance brokenIn immune-tolerant HBV patients who typically ignore the virus, thymosin alpha-1 + famciclovir activated specific anti-HBV T-cells — breaking immune silence
What the researchers found
Thymosin alpha-1 + famciclovir combination activated HBV-specific T-cell responses and achieved HBeAg seroconversion in some immune-tolerant chronic hepatitis B patients — a typically treatment-unresponsive population.
Why it matters
Immune-tolerant HBV carriers are the largest reservoir of the virus. If their immune tolerance can be broken with combination therapy, HBV global elimination becomes more achievable.
How the study worked
Clinical trial in immune-tolerant chronic HBV patients (high HBV DNA, normal ALT). Combined thymosin alpha-1 + famciclovir therapy. HBeAg seroconversion, HBV DNA levels, and HBV-specific T-cell responses monitored.
What this study cannot tell us
Small study with limited seroconversion rate details. Immune-tolerant HBV is heterogeneous. Long-term durability of seroconversion not established.
How to read the evidence
Moderate evidence from a clinical trial in the relevant (and most difficult to treat) HBV population, showing both immunological and virological responses.
When this study was published
Published in 2002. Thymosin alpha-1 combined with antivirals remains an active area of HBV cure research.
The bigger picture
Breaking immune tolerance in chronic HBV is the holy grail of hepatitis B therapy. Thymosin alpha-1's immune-activating properties combined with an antiviral that reduces viral load may create a window for immune reconversion.
Questions still open
- Can thymosin alpha-1 break immune tolerance when combined with newer HBV antivirals?
- What predicts which immune-tolerant patients will respond?
- Should thymosin alpha-1 be combined with checkpoint inhibitors for HBV?
Common questions
What is immune-tolerant hepatitis B?
Why is breaking tolerance important?
Read the original research
Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase.
Journal of viral hepatitis, 9(4), 280-7
Citation
Lau, G K K; Nanji, A; Hou, J; Fong, D Y T; Au, W-S; Yuen, S-T; Lin, M; Kung, H-F; Lam, S-K. (2002). Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase.. Journal of viral hepatitis, 9(4), 280-7.